News

Jan 28, 2014 – Viteava Pharmaceuticals Announces Research Agreement with McGill University and Leveraging of Federal Grants

TORONTO, Canada. Viteava Pharmaceuticals Inc. announced the execution of a sponsored research agreement with McGill University relating to novel analogs and derivatives of the green tea flavonoid, (-)epigallocatechin-3-gallate (EGCG). View the PDF

Nov 19, 2013 – Viteava Pharmaceuticals Executes Worldwide Exclusive License

TORONTO, Canada. Viteava Pharmaceuticals Inc. announced the execution of an exclusive worldwide license to an intellectual property portfolio claiming composition of matter and/or methods of use of novel analogs and derivatives of the green tea flavonoid, (-)epigallocatechin-3-gallate (EGCG). View the PDF